Recursion Historical Cash Flow

RXRX Stock  USD 6.38  0.49  8.32%   
Analysis of Recursion Pharmaceuticals cash flow over time is an excellent tool to project Recursion Pharmaceuticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 25.6 M or Other Non Cash Items of 13.3 M as it is a great indicator of Recursion Pharmaceuticals ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Recursion Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Recursion Pharmaceuticals is a good buy for the upcoming year.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

About Recursion Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Recursion balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Recursion's non-liquid assets can be easily converted into cash.

Recursion Pharmaceuticals Cash Flow Chart

At this time, Recursion Pharmaceuticals' Stock Based Compensation is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 587.1 M in 2024, whereas Investments are likely to drop (16.5 M) in 2024.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Recursion Pharmaceuticals value has been used up. For tax purposes Recursion Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Recursion Pharmaceuticals must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.
Most accounts from Recursion Pharmaceuticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Recursion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Recursion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.At this time, Recursion Pharmaceuticals' Stock Based Compensation is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 587.1 M in 2024, whereas Investments are likely to drop (16.5 M) in 2024.
 2023 2024 (projected)
Sale Purchase Of Stock424.2M377.1M
Change To Inventory1.8K1.7K

Recursion Pharmaceuticals cash flow statement Correlations

0.440.660.070.230.56-0.040.020.19-0.110.03-0.69-0.7-0.030.240.140.29-0.660.040.040.04-0.04
0.440.22-0.580.70.94-0.57-0.62-0.390.080.80.27-0.210.480.0-0.39-0.360.250.750.750.75-0.77
0.660.22-0.160.410.11-0.27-0.16-0.2-0.670.0-0.31-0.720.29-0.2-0.23-0.02-0.380.010.010.01-0.01
0.07-0.58-0.16-0.95-0.30.991.00.970.54-0.92-0.710.39-0.980.790.970.96-0.77-0.88-0.88-0.880.87
0.230.70.41-0.950.45-0.97-0.96-0.89-0.580.890.49-0.580.95-0.7-0.91-0.840.550.830.830.83-0.87
0.560.940.11-0.30.45-0.29-0.35-0.070.340.610.0-0.130.180.3-0.08-0.060.00.570.570.57-0.59
-0.04-0.57-0.270.99-0.97-0.290.990.960.63-0.88-0.610.52-0.990.820.970.94-0.68-0.85-0.85-0.850.84
0.02-0.62-0.161.0-0.96-0.350.990.950.52-0.94-0.680.42-0.970.760.960.95-0.75-0.89-0.89-0.890.89
0.19-0.39-0.20.97-0.89-0.070.960.950.68-0.8-0.740.39-0.990.91.00.98-0.79-0.76-0.76-0.760.76
-0.110.08-0.670.54-0.580.340.630.520.68-0.2-0.160.73-0.680.810.70.57-0.19-0.25-0.25-0.250.16
0.030.80.0-0.920.890.61-0.88-0.94-0.8-0.20.66-0.230.83-0.51-0.8-0.820.720.930.930.93-0.96
-0.690.27-0.31-0.710.490.0-0.61-0.68-0.74-0.160.660.330.64-0.54-0.69-0.790.970.610.610.61-0.63
-0.7-0.21-0.720.39-0.58-0.130.520.420.390.73-0.230.33-0.50.490.450.290.22-0.28-0.28-0.280.2
-0.030.480.29-0.980.950.18-0.99-0.97-0.99-0.680.830.64-0.5-0.87-0.99-0.960.710.780.780.78-0.81
0.240.0-0.20.79-0.70.30.820.760.90.81-0.51-0.540.49-0.870.910.88-0.64-0.47-0.47-0.470.51
0.14-0.39-0.230.97-0.91-0.080.970.961.00.7-0.8-0.690.45-0.990.910.98-0.76-0.77-0.77-0.770.76
0.29-0.36-0.020.96-0.84-0.060.940.950.980.57-0.82-0.790.29-0.960.880.98-0.87-0.79-0.79-0.790.78
-0.660.25-0.38-0.770.550.0-0.68-0.75-0.79-0.190.720.970.220.71-0.64-0.76-0.870.670.670.67-0.68
0.040.750.01-0.880.830.57-0.85-0.89-0.76-0.250.930.61-0.280.78-0.47-0.77-0.790.671.01.0-0.8
0.040.750.01-0.880.830.57-0.85-0.89-0.76-0.250.930.61-0.280.78-0.47-0.77-0.790.671.01.0-0.8
0.040.750.01-0.880.830.57-0.85-0.89-0.76-0.250.930.61-0.280.78-0.47-0.77-0.790.671.01.0-0.8
-0.04-0.77-0.010.87-0.87-0.590.840.890.760.16-0.96-0.630.2-0.810.510.760.78-0.68-0.8-0.8-0.8
Click cells to compare fundamentals

Recursion Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.